Robust sales pipeline and rising revenues at life sciences group
Aptamer Group, a developer of novel Optimer® binders to enable innovation in the life sciences industry, has hailed commercial and technical progress in a trading update for the six months ending 31 December 2024 (H1 25).
Unaudited revenue for the year’s first half was £0.7m, compared with £0.3m over the same period during the last financial year.
Also, the York-headquartered group has secured commercial contracts with a value of up to £0.7m. Newly signed contracts over the first half of the financial year include five fee-for-service development projects with the top 20 pharmaceutical companies.
Dr Arron Tolley, chief executive officer, said: “In the first half of the year, we have achieved significant commercial and technical progress across the group.
“From a commercial perspective, revenue has improved substantially, and forward visibility is supported by a robust pipeline of projects which are advancing in our labs.
“Many of these are repeat business from major pharmaceutical clients, reinforcing and further validating the growing demand for our innovative technologies across the life sciences industry.”
As of 31 December 2024, Aptamer had about £0.5m worth of contracted work in preparation for processing through its laboratory, which the group expects to recognise as revenue in the second half of the financial year.
The sales pipeline stands at £4.8m, including £3.4m in advanced negotiations. The group anticipates converting a portion of this pipeline during the second half of the financial year, further enhancing its revenue outlook for the second half and into next year.
